What is the recommended dosing schedule for etoposide and cisplatin in adult patients with small-cell lung cancer, including dose adjustments for age, renal or hepatic impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Etoposide and Cisplatin Dosing in SCLC

For small-cell lung cancer, use cisplatin 75 mg/m² on day 1 with etoposide 100 mg/m² on days 1,2, and 3, repeated every 21 days for 4 cycles in limited-stage disease or 4-6 cycles in extensive-stage disease. 1

Limited-Stage SCLC (with concurrent radiotherapy)

The NCCN 2026 guidelines provide clear Category 1 recommendations for dosing during concurrent chemoradiotherapy 1:

Preferred Regimens:

  • Cisplatin 75 mg/m² day 1 + Etoposide 100 mg/m² days 1,2,3 (every 21-28 days)
  • Cisplatin 60 mg/m² day 1 + Etoposide 120 mg/m² days 1,2,3
  • Alternative: Cisplatin 25 mg/m² days 1,2,3 + Etoposide 100 mg/m² days 1,2,3

Treatment duration: 4 cycles during concurrent radiotherapy 1, 2

The ASCO-Ontario Health guideline confirms cisplatin 60-80 mg/m² on day 1 with etoposide 100-120 mg/m² on days 1,2, and 3 as standard dosing, emphasizing attempts to minimize dose reductions especially during the first two cycles 2.

Extensive-Stage SCLC

Preferred Regimens (with immunotherapy):

  • Cisplatin 75-80 mg/m² day 1 + Etoposide 80-100 mg/m² days 1,2,3 + Durvalumab 1500 mg day 1 every 21 days × 4 cycles (Category 1) 1
  • Carboplatin AUC 5 day 1 + Etoposide 100 mg/m² days 1,2,3 + Atezolizumab 1200 mg day 1 every 21 days × 4 cycles (Category 1) 1

Without Immunotherapy:

  • Cisplatin 75 mg/m² day 1 + Etoposide 100 mg/m² days 1,2,3
  • Cisplatin 80 mg/m² day 1 + Etoposide 80 mg/m² days 1,2,3

Treatment duration: 4 cycles recommended, though some patients may receive up to 6 cycles based on response and tolerability 1

Dose Adjustments

Renal Impairment:

The FDA label provides specific guidance for etoposide dose reduction 3:

Creatinine Clearance Etoposide Dose
>50 mL/min 100% of dose
15-50 mL/min 75% of dose
<15 mL/min Further reduction required

Cisplatin contraindication: Cisplatin should not be used with creatinine clearance <60 mL/min according to German SmPC 4. In such cases, substitute carboplatin AUC 5-6 1, 2.

Hepatic Impairment:

While specific hepatic dosing adjustments are not detailed in the guidelines, patients with low serum albumin are at increased risk for etoposide-associated toxicities and require careful monitoring 3.

Age Considerations:

No specific dose reductions are recommended based on age alone. However, elderly patients (≥65 years) experience increased frequency of WHO Grade III-IV leukopenia and should be monitored closely 3. The standard doses remain appropriate with careful toxicity monitoring.

Administration Details

Etoposide administration: Must be diluted to 0.2-0.4 mg/mL and infused over 30-60 minutes to prevent hypotension 3. Rapid IV injection is contraindicated.

Cisplatin administration: Standard hydration protocols should be followed to minimize nephrotoxicity.

Critical Pitfalls to Avoid

  1. Do NOT use myeloid growth factors during concurrent chemoradiotherapy plus RT (Category 1 recommendation against GM-CSF use) 1

  2. Do NOT give rapid IV etoposide - hypotension risk requires 30-60 minute infusion 3

  3. Do NOT continue beyond 4 cycles in limited-stage disease - no survival benefit demonstrated for extending to 6 cycles 2

  4. Do NOT use cisplatin if creatinine clearance <60 mL/min - switch to carboplatin 4

  5. Minimize dose reductions during first two cycles when possible, as this impacts outcomes 2

Carboplatin Substitution

When cisplatin is contraindicated (renal impairment, neuropathy, ototoxicity, or hypersensitivity), carboplatin AUC 5-6 may be substituted with etoposide 100 mg/m² days 1,2,3 1, 2. While one randomized trial showed no significant OS difference between cisplatin/etoposide and carboplatin/etoposide regimens, cisplatin remains preferred when tolerable 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.